Anne-Laure Dreno, country president of AstraZeneca in Belgium, elaborates on the significant position Belgium and the local affiliate have for the group as a frontrunner in innovative areas such as creating value-based agreements for reimbursements, (clinical) research and development, and embracing the opportunities of patient data. Dreno also discusses her mission to align the affiliate with the global strategy of AstraZeneca to ensure patient access to innovation in key therapeutic areas through partnership with health authorities.
As we prepare for the next steps of the AstraZeneca journey, there is an increased focus beyond the pipeline on innovative approaches in areas like patient-centricity and access where we are aiming for value-based contracts, leveraging innovative technologies such as AI
Tags:
